GR3036487T3 - Stable pura vectors and uses thereof. - Google Patents
Stable pura vectors and uses thereof.Info
- Publication number
- GR3036487T3 GR3036487T3 GR20010401346T GR20010401346T GR3036487T3 GR 3036487 T3 GR3036487 T3 GR 3036487T3 GR 20010401346 T GR20010401346 T GR 20010401346T GR 20010401346 T GR20010401346 T GR 20010401346T GR 3036487 T3 GR3036487 T3 GR 3036487T3
- Authority
- GR
- Greece
- Prior art keywords
- selection
- complementation
- stable
- vectors
- maintenance
- Prior art date
Links
- 101150002764 purA gene Proteins 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000005291 Adenylosuccinate synthase Human genes 0.000 abstract 1
- 108010056443 Adenylosuccinate synthase Proteins 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 206010061764 Chromosomal deletion Diseases 0.000 abstract 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 230000002759 chromosomal effect Effects 0.000 abstract 1
- 230000004151 fermentation Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000027086 plasmid maintenance Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/68—Stabilisation of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69570691A | 1991-05-03 | 1991-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GR3036487T3 true GR3036487T3 (en) | 2001-11-30 |
Family
ID=24794162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GR20010401346T GR3036487T3 (en) | 1991-05-03 | 2001-08-31 | Stable pura vectors and uses thereof. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US5919663A (enExample) |
| EP (1) | EP0512260B1 (enExample) |
| JP (1) | JP3320095B2 (enExample) |
| KR (1) | KR100242798B1 (enExample) |
| AT (1) | ATE202800T1 (enExample) |
| AU (1) | AU654347B2 (enExample) |
| CA (1) | CA2067862C (enExample) |
| DE (1) | DE69231907T2 (enExample) |
| DK (1) | DK0512260T3 (enExample) |
| ES (1) | ES2160573T3 (enExample) |
| FI (1) | FI111013B (enExample) |
| GR (1) | GR3036487T3 (enExample) |
| IL (1) | IL101751A0 (enExample) |
| NO (1) | NO314043B1 (enExample) |
| PT (1) | PT512260E (enExample) |
| TW (1) | TW201794B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
| US7279313B2 (en) * | 1995-09-15 | 2007-10-09 | Centelion | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy |
| EP0927246A2 (de) * | 1996-09-04 | 1999-07-07 | Basf Aktiengesellschaft | Adenylosuccinat synthetase |
| US6350454B1 (en) * | 1997-04-11 | 2002-02-26 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Attenuated Pasteurella piscicida vaccine for fish |
| US6010705A (en) * | 1997-04-11 | 2000-01-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Attenuated, invasive vaccines against fish pathogens |
| AU772356B2 (en) * | 1998-12-04 | 2004-04-22 | Aventis Pasteur Limited | Two-step immunization procedure against chlamydia infection |
| KR100427587B1 (ko) * | 2001-01-12 | 2004-04-27 | 주식회사 바이오리더스 | 신규 ｄ-글루탐산 합성효소 유전자 ｄｎａ 및 이를 이용한 항생제 비의존성 벡터 |
| FI116851B (fi) * | 2001-05-03 | 2006-03-15 | Fit Biotech Oyj Plc | Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita |
| US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| CN1646020A (zh) * | 2002-01-31 | 2005-07-27 | 圣必健公司 | 将核酸和/或蛋白质导入呼吸系统的方法与制剂 |
| CN1276076C (zh) * | 2004-12-14 | 2006-09-20 | 华东理工大学 | 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用 |
| WO2009025888A2 (en) | 2007-05-10 | 2009-02-26 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Regulated synthesis of antigen and/or regulated attentuation to enhance vaccine immunogenics and/or safety |
| US20100317084A1 (en) * | 2007-05-10 | 2010-12-16 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens |
| WO2009046451A1 (en) | 2007-10-05 | 2009-04-09 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting a protective immune response against c. perfringens |
| WO2010045620A1 (en) * | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
| US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
| GB2483595B (en) | 2009-05-22 | 2017-03-29 | The Arizona Board Of Regents For And On Behalf Of Arizona State Univ | Recombinant bacterium and methods of antigen and nucleic acid delivery |
| US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
| US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
| EP2526185A4 (en) | 2010-01-22 | 2013-07-24 | Univ Arizona | BACTERIUM WITH REGULATED RFAH NUCLEIC ACID |
| US9598697B2 (en) | 2010-05-28 | 2017-03-21 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
| WO2012082946A2 (en) * | 2010-12-14 | 2012-06-21 | The Regents Of The University Of California | Creation of super-stable coie1 plasmids by duplication of sl 1-4 sequence and point mutations. |
| US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
| US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
| KR102006976B1 (ko) * | 2019-02-26 | 2019-08-06 | 씨제이제일제당 주식회사 | 신규 프로모터 및 이를 이용한 퓨린 뉴클레오티드 제조방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0025118A1 (de) * | 1979-08-18 | 1981-03-18 | Riedlinger, Rainer, Dr.-Ing. | Anordnung zur akustischen Wiedergabe von Signalen, die mittels eines rechten und eines linken Stereo-Kanals darstellbar sind |
| US4735801A (en) * | 1982-09-07 | 1988-04-05 | Board Of Trustees Of Leland Stanford Jr. University | Novel non-reverting salmonella live vaccines |
| US4550081A (en) * | 1980-05-19 | 1985-10-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Non-reverting salmonella |
| US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
| DK410783D0 (da) * | 1982-09-16 | 1983-09-09 | Benzon A Salfred | Fremgangsmade til stabilisering af plasmider |
| EP0251579A3 (en) * | 1986-06-24 | 1989-03-22 | Enterovax Research Pty. Ltd. | Non-antibiotic marker system |
| DK408687A (da) * | 1986-08-05 | 1988-02-06 | Transgene Sa | Fremgangsmaade til stabilisering af et plasmid |
| JPS6427477A (en) * | 1987-04-01 | 1989-01-30 | Takeda Chemical Industries Ltd | Dna and use thereof |
| US5112749A (en) * | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| GB8730037D0 (en) * | 1987-12-23 | 1988-02-03 | Wellcome Found | Vaccines |
| AU5432690A (en) * | 1989-03-31 | 1990-11-05 | Washington University | Bordetella vaccines |
| CA2097931C (en) * | 1990-12-18 | 2003-07-29 | Samuel I. Miller, Iii | Salmonella vaccines |
-
1992
- 1992-02-11 TW TW081100950A patent/TW201794B/zh active
- 1992-04-06 DE DE69231907T patent/DE69231907T2/de not_active Expired - Fee Related
- 1992-04-06 DK DK92105887T patent/DK0512260T3/da active
- 1992-04-06 EP EP92105887A patent/EP0512260B1/en not_active Expired - Lifetime
- 1992-04-06 AT AT92105887T patent/ATE202800T1/de not_active IP Right Cessation
- 1992-04-06 PT PT92105887T patent/PT512260E/pt unknown
- 1992-04-06 ES ES92105887T patent/ES2160573T3/es not_active Expired - Lifetime
- 1992-04-28 JP JP13437592A patent/JP3320095B2/ja not_active Expired - Fee Related
- 1992-04-30 NO NO19921729A patent/NO314043B1/no unknown
- 1992-04-30 IL IL101751A patent/IL101751A0/xx not_active IP Right Cessation
- 1992-04-30 FI FI921940A patent/FI111013B/fi not_active IP Right Cessation
- 1992-05-01 CA CA002067862A patent/CA2067862C/en not_active Expired - Fee Related
- 1992-05-01 AU AU15959/92A patent/AU654347B2/en not_active Ceased
- 1992-05-02 KR KR1019920007559A patent/KR100242798B1/ko not_active Expired - Fee Related
-
1995
- 1995-01-30 US US08/380,297 patent/US5919663A/en not_active Expired - Fee Related
- 1995-05-24 US US08/448,907 patent/US5961983A/en not_active Expired - Fee Related
-
2001
- 2001-08-31 GR GR20010401346T patent/GR3036487T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201794B (enExample) | 1993-03-11 |
| DE69231907T2 (de) | 2001-10-18 |
| EP0512260A3 (en) | 1993-07-28 |
| CA2067862C (en) | 2003-12-30 |
| NO314043B1 (no) | 2003-01-20 |
| AU1595992A (en) | 1992-11-05 |
| JPH05192161A (ja) | 1993-08-03 |
| DK0512260T3 (da) | 2001-09-17 |
| JP3320095B2 (ja) | 2002-09-03 |
| FI111013B (fi) | 2003-05-15 |
| US5961983A (en) | 1999-10-05 |
| NO921729L (no) | 1992-11-04 |
| KR100242798B1 (ko) | 2000-02-01 |
| IL101751A0 (en) | 1992-12-30 |
| US5919663A (en) | 1999-07-06 |
| FI921940L (fi) | 1992-11-04 |
| KR920021701A (ko) | 1992-12-18 |
| PT512260E (pt) | 2001-12-28 |
| ES2160573T3 (es) | 2001-11-16 |
| DE69231907D1 (de) | 2001-08-09 |
| EP0512260B1 (en) | 2001-07-04 |
| CA2067862A1 (en) | 1992-11-04 |
| NO921729D0 (no) | 1992-04-30 |
| FI921940A0 (fi) | 1992-04-30 |
| AU654347B2 (en) | 1994-11-03 |
| ATE202800T1 (de) | 2001-07-15 |
| EP0512260A2 (en) | 1992-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0512260A3 (en) | Stable pura vectors and uses thereof | |
| Galán et al. | Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains | |
| Taylor et al. | Safe, live Vibrio cholerae vaccines? | |
| TW205567B (enExample) | ||
| O'Callaghan et al. | High efficiency transformation of Salmonella typhimurium and Salmonella typhi by electroporation | |
| Knapp et al. | Two trans-acting regulatory genes (vir and mod) control antigenic modulation in Bordetella pertussis | |
| EP0400958B1 (en) | Live vaccines | |
| Kutyrev et al. | Analysis of Yersinia pestis chromosomal determinants Pgm+ and Psts associated with virulence | |
| Kwaga et al. | A carAB mutant of avian pathogenic Escherichia coli serogroup O2 is attenuated and effective as a live oral vaccine against colibacillosis in turkeys | |
| Williamson et al. | Identification of an essential virulence region on Salmonella plasmids | |
| JP2002511752A (ja) | 生弱毒ワクチン | |
| Miller et al. | The PhoP virulence regulon and live oral Salmonella vaccines | |
| PL343246A1 (en) | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines | |
| KR20080082156A (ko) | ｌｏｎ 유전자 및／또는 ｃｐｘＲ 유전자가 결실된살모넬라 변이균주 및 이를 함유하는 살모넬라 생백신 | |
| KR102774793B1 (ko) | 폐렴구균 표면 단백질 A(PspA)의 발현 | |
| Sandoval et al. | Screening of plasmids in non-pathogenic corynebacteria | |
| Leong et al. | Molecular analysis of iron transport in plant growth-promoting Pseudomonas putida WCS358 | |
| Veken et al. | Binding of host iron-binding proteins and expression of iron-regulated membrane proteins by different serotypes ofPasteurella multocidacausing haemorrhagic septicaemia | |
| RU94037007A (ru) | Вакцина против стрептококкоза и пастереллеза нутрий | |
| Kasuga et al. | Drug resistance of staphylococci VIII. Genetic properties of resistance to tetracycline in Staphylococcus aureus E169 | |
| McPheat et al. | Phase I and phase IV strains of Bordetella pertussis carry a repeated DNA sequence not found in other Bordetella species | |
| Fujiwara et al. | Construction of shuttle vectors derived from Acetobacter xylinum for cellulose-producing bacterium Acetobacter xylinum | |
| Datta et al. | Effect of vibriocins on members of the Enterobacteriaceae | |
| JPS57206699A (en) | Plasmid patm 3 and its preparation | |
| AU558008B2 (en) | Ozone inactivated organisms as vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ML | Lapse due to non-payment of fees |